Treatment of affective disorders in cardiac disease

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Patients with cardiovascular disease (CVD) commonly have syndromal major depression, and depression has been associated with an increased risk of morbidity and mortality. Prevalence of depression is between 17% and 47% in CVD patients. Pharmacologic and psychotherapeutic interventions have long been studied, and in general are safe and somewhat efficacious in decreasing depressive symptoms in patients with CVD. The impact on cardiac outcomes remains unclear. The evidence from randomized controlled clinical trials indicates that anti-depressants, especially selective serotonin uptake inhibitors, are overwhelmingly safe, and likely to be effective in the treatment of depression in patients with CVD. This review describes the prevalence of depression in patients with CVD, the physiological links between depression and CVD, the treatment options for affective disorders, and the clinical trials that demonstrate efficacy and safety of antidepressant medications and psychotherapy in this patient population. Great progress has been made in understanding potential mediators between major depressive disorder and CVD-both health behaviors and shared biological risks such as inflammation.

Original languageEnglish (US)
Pages (from-to)127-140
Number of pages14
JournalDialogues in Clinical Neuroscience
Volume17
Issue number2
StatePublished - 2015

Fingerprint

Mood Disorders
Heart Diseases
Cardiovascular Diseases
Depression
Therapeutics
Health Behavior
Major Depressive Disorder
Serotonin Uptake Inhibitors
Psychotherapy
Antidepressive Agents
Randomized Controlled Trials
Clinical Trials
Inflammation
Morbidity
Safety
Mortality
Population

Keywords

  • Antidepressant
  • Anxiety
  • Cardiac disease
  • Cardiovascular disease
  • Coronary artery syndrome
  • Depression
  • Post-MI
  • SSRI
  • Treatment of depression or anxiety

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Treatment of affective disorders in cardiac disease. / Mavrides, Nicole A; Nemeroff, Charles.

In: Dialogues in Clinical Neuroscience, Vol. 17, No. 2, 2015, p. 127-140.

Research output: Contribution to journalArticle

@article{691d624ef15041bca6ad55aa2ad1de53,
title = "Treatment of affective disorders in cardiac disease",
abstract = "Patients with cardiovascular disease (CVD) commonly have syndromal major depression, and depression has been associated with an increased risk of morbidity and mortality. Prevalence of depression is between 17{\%} and 47{\%} in CVD patients. Pharmacologic and psychotherapeutic interventions have long been studied, and in general are safe and somewhat efficacious in decreasing depressive symptoms in patients with CVD. The impact on cardiac outcomes remains unclear. The evidence from randomized controlled clinical trials indicates that anti-depressants, especially selective serotonin uptake inhibitors, are overwhelmingly safe, and likely to be effective in the treatment of depression in patients with CVD. This review describes the prevalence of depression in patients with CVD, the physiological links between depression and CVD, the treatment options for affective disorders, and the clinical trials that demonstrate efficacy and safety of antidepressant medications and psychotherapy in this patient population. Great progress has been made in understanding potential mediators between major depressive disorder and CVD-both health behaviors and shared biological risks such as inflammation.",
keywords = "Antidepressant, Anxiety, Cardiac disease, Cardiovascular disease, Coronary artery syndrome, Depression, Post-MI, SSRI, Treatment of depression or anxiety",
author = "Mavrides, {Nicole A} and Charles Nemeroff",
year = "2015",
language = "English (US)",
volume = "17",
pages = "127--140",
journal = "Dialogues in Clinical Neuroscience",
issn = "1294-8322",
publisher = "Servier International",
number = "2",

}

TY - JOUR

T1 - Treatment of affective disorders in cardiac disease

AU - Mavrides, Nicole A

AU - Nemeroff, Charles

PY - 2015

Y1 - 2015

N2 - Patients with cardiovascular disease (CVD) commonly have syndromal major depression, and depression has been associated with an increased risk of morbidity and mortality. Prevalence of depression is between 17% and 47% in CVD patients. Pharmacologic and psychotherapeutic interventions have long been studied, and in general are safe and somewhat efficacious in decreasing depressive symptoms in patients with CVD. The impact on cardiac outcomes remains unclear. The evidence from randomized controlled clinical trials indicates that anti-depressants, especially selective serotonin uptake inhibitors, are overwhelmingly safe, and likely to be effective in the treatment of depression in patients with CVD. This review describes the prevalence of depression in patients with CVD, the physiological links between depression and CVD, the treatment options for affective disorders, and the clinical trials that demonstrate efficacy and safety of antidepressant medications and psychotherapy in this patient population. Great progress has been made in understanding potential mediators between major depressive disorder and CVD-both health behaviors and shared biological risks such as inflammation.

AB - Patients with cardiovascular disease (CVD) commonly have syndromal major depression, and depression has been associated with an increased risk of morbidity and mortality. Prevalence of depression is between 17% and 47% in CVD patients. Pharmacologic and psychotherapeutic interventions have long been studied, and in general are safe and somewhat efficacious in decreasing depressive symptoms in patients with CVD. The impact on cardiac outcomes remains unclear. The evidence from randomized controlled clinical trials indicates that anti-depressants, especially selective serotonin uptake inhibitors, are overwhelmingly safe, and likely to be effective in the treatment of depression in patients with CVD. This review describes the prevalence of depression in patients with CVD, the physiological links between depression and CVD, the treatment options for affective disorders, and the clinical trials that demonstrate efficacy and safety of antidepressant medications and psychotherapy in this patient population. Great progress has been made in understanding potential mediators between major depressive disorder and CVD-both health behaviors and shared biological risks such as inflammation.

KW - Antidepressant

KW - Anxiety

KW - Cardiac disease

KW - Cardiovascular disease

KW - Coronary artery syndrome

KW - Depression

KW - Post-MI

KW - SSRI

KW - Treatment of depression or anxiety

UR - http://www.scopus.com/inward/record.url?scp=84940785827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940785827&partnerID=8YFLogxK

M3 - Article

C2 - 26246788

AN - SCOPUS:84940785827

VL - 17

SP - 127

EP - 140

JO - Dialogues in Clinical Neuroscience

JF - Dialogues in Clinical Neuroscience

SN - 1294-8322

IS - 2

ER -